PAR 2.56% 20.0¢ paradigm biopharmaceuticals limited..

Branching out..., page-2

  1. 615 Posts.
    lightbulb Created with Sketch. 258
    Great initiative Mozz. I and others have written it before, that to grow the shareholder base in the US (where the dedicated funds with halo effects, reside) they need a US listing.
    I am sure the truly adventurous will find a way, but for the vast majority, they will not venture to their computer screens after dinner to trade something in our day, their night.
    Yes, managements focus needed / needs to be on the trials and it would seem the company has even less hands on deck now that there is another departure (board member), so hopefully any new additions to the board will have some expertise in this area.
 
watchlist Created with Sketch. Add PAR (ASX) to my watchlist
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.